Drugs / DLQ01
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05636904 | Dec 2022 → Mar 2024 | androgenetic alopecia | Dermaliq Therapeutics, Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-07-16 | Dermaliq Therapeutics, Inc. | Results Dermaliq Therapeutics announces positive topline results from Phase 1b/2a trial evaluating the safety and efficacy of DLQ01 for the treatment of androgenetic alopecia (AGA) in men dermaliq.com ↗
DLQ01 treatment increased TAHC by 12.3% from baseline, with a highly statistical significance (p=0.008) compared to vehicle. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-07-16 | Dermaliq Therapeutics, Inc. | Dermaliq Therapeutics announces positive topline results from Phase 1b/2a trial evaluating the safety and efficacy of DLQ01 for the treatment of androgenetic alopecia (AGA) in men dermaliq.com ↗ |
| 2022-12-15 | Dermaliq Therapeutics, Inc. | Dermaliq Therapeutics announces first participant randomized in Phase 1b/2 trial evaluating DLQ01 solution for treatment of androgenic alopecia dermaliq.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DLQ01 | “The goal of this study is to measure the safety, tolerability, and the hair growth response to topical DLQ01 solutions in comparison to the vehicle and a comparator solution in...” NCT05636904 ↗ |
| Route | Topical | “Topical treatment for 24 weeks” NCT05636904 ↗ |